{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:09:14Z","timestamp":1771466954149,"version":"3.50.1"},"reference-count":21,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/14712598.2025.2508836","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T04:23:24Z","timestamp":1747801404000},"page":"593-598","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?"],"prefix":"10.1080","volume":"25","author":[{"given":"Sheila A.","family":"Doggrell","sequence":"first","affiliation":[{"name":"Gold Coast Campus, Griffith University","place":["Gold Coast, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01927-5"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03183-x"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010121"},{"key":"e_1_3_3_7_1","unstructured":"Astra-Zeneca. Update on brazikumab development programme. [cited 2025 Feb 17]. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/update-on-brazikumab-development-programme.html"},{"key":"e_1_3_3_8_1","unstructured":"Pharmacy Times. FDA approves guselkumab for treatment of ulcerative colitis. [cited 2025 Feb 17]. Available from: https:\/\/www.pharmacytimes.com\/view\/fda-approves-guselkumab-for-treatment-of-ulcerative-colitis"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00427-7"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.08.038"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0023"},{"issue":"3","key":"e_1_3_3_12_1","first-page":"9","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results for the phase 3 QUASAR induction study","volume":"7","year":"2023","unstructured":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results for the phase 3 QUASAR induction study. Gastroenterol Hepatol (NY). 2023;7(Suppl 3):9\u201310.","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"9","key":"e_1_3_3_13_1","first-page":"2","article-title":"Early symptomatic improvement with guselkumab induction treatment in moderately to severely active ulcerative colitis: results from the phase 3 QUASAR study","volume":"12","year":"2023","unstructured":"Early symptomatic improvement with guselkumab induction treatment in moderately to severely active ulcerative colitis: results from the phase 3 QUASAR study. Gastroenterol Hepatol (NY). 2023;12(Suppl 9):2\u20133.","journal-title":"Gastroenterol Hepatol (NY)"},{"issue":"6","key":"e_1_3_3_14_1","first-page":"9","article-title":"The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR maintenance study","volume":"20","year":"2024","unstructured":"The efficacy and safety of guselkumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR maintenance study. Gastroenterol Hepatol (NY). 2024;20(Suppl 6):9\u201310.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02262-1"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.07.046"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12414"},{"key":"e_1_3_3_19_1","unstructured":"Atreya R Abreu MT Kueger JG et al. P504 guselkumab an IL-23p19 subunit\u2013specific monoclonal antibody binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. [cited 2025 Mar 12]. Available from: https:\/\/www.ecco-ibd.eu\/publications\/congress-abstracts\/item\/p504-guselkumab-an-il-23p19-subunit-specific-monoclonal-antibody-binds-cd64-myeloid-cells-and-potently-neutralises-il-23-produced-from-the-same-cells.html"},{"key":"e_1_3_3_20_1","unstructured":"Clinicaltrials.gov. A study of guselkumab therapy in participants with moderately to severely active ulcerative colitis (ASTRO). [cited 2025 Feb 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05528510?cond=Ulcerative%20Colitis&intr=guselkumab&rank=2"},{"key":"e_1_3_3_21_1","unstructured":"Clinicaltrials.gov. A study of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (DUET-UC). [cited 2025 Feb 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05242484?cond=Ulcerative%20Colitis&intr=guselkumab&rank=4#participation-criteria"},{"key":"e_1_3_3_22_1","unstructured":"Clinicaltrials.gov. A study of guselkumab in pediatric participants with moderately to severely active ulcerative colitis (QUASAR Jr). [cited 2025 Feb 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06260163?cond=Ulcerative%20Colitis&intr=guselkumab&rank=1"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020608"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2025.2508836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:32:23Z","timestamp":1749814343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2025.2508836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/14712598.2025.2508836"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2025.2508836","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}